Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report released on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock.

Other analysts also recently issued research reports about the stock. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Wednesday, July 1st. Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Roth Capital restated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Finally, Weiss Ratings downgraded Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Gain Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Trading Up 16.4%

Shares of GANX opened at $2.06 on Tuesday. The company’s fifty day simple moving average is $1.79 and its 200-day simple moving average is $1.93. The company has a market cap of $87.86 million, a P/E ratio of -3.55 and a beta of 0.19. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a twelve month low of $1.46 and a twelve month high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. As a group, analysts expect that Gain Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Apollon Wealth Management LLC raised its holdings in shares of Gain Therapeutics by 33.7% in the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock valued at $51,000 after purchasing an additional 6,675 shares in the last quarter. Geode Capital Management LLC grew its stake in Gain Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares during the last quarter. Sprott Inc. purchased a new stake in shares of Gain Therapeutics during the fourth quarter valued at about $39,000. Commonwealth Equity Services LLC bought a new position in shares of Gain Therapeutics during the 4th quarter worth approximately $41,000. Finally, Millennium Management LLC purchased a new position in Gain Therapeutics in the fourth quarter worth $45,000. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.